Peptides Containing Saccharide Radicals, E.g., Bleomycins, Etc. Patents (Class 530/322)
-
Publication number: 20120135941Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘C terminus of HSP70-Interacting Protein’ (CHIP), in particular, by targeting natural antisense polynucleotides of ‘C terminus of HSP70-Interacting Protein’ (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.Type: ApplicationFiled: August 20, 2010Publication date: May 31, 2012Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
-
Publication number: 20120135919Abstract: A conjugate that includes a drug covalently linked to a polymer. Upon administration, the conjugate is digested by an enzyme that is present at the site of administration thereby releasing a therapeutic agent. The conjugate may demonstrate substantially the same pharmacokinetic and pharmacodynamic behavior as the drug itself. A material for controllably releasing a conjugate in response to the local concentration of a molecular indicator. The material includes a plurality of conjugates and a plurality of multivalent cross-linking agents. The polymers of the conjugates include an analog of the indicator within their covalent structure. The multivalent cross-linking agents include cross-link receptors that interact with the indicator analog and thereby cross-link the conjugates.Type: ApplicationFiled: February 6, 2012Publication date: May 31, 2012Applicant: SMARTCELLS, INC.Inventors: Thomas M. Lancaster, Matthew Nalewanski, Todd C. Zion
-
Publication number: 20120136042Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.Type: ApplicationFiled: December 14, 2011Publication date: May 31, 2012Applicant: ALNYLAM PHARMACEUTICALS, INCInventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Narayanannair K. JAYAPRAKASH, Martin MAIER
-
Publication number: 20120134931Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.Type: ApplicationFiled: July 15, 2010Publication date: May 31, 2012Applicant: REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Roger Tsien, Tood Aguilera, Emilia Olson, Tao Jiang, Quyen Nguyen
-
Publication number: 20120135912Abstract: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.Type: ApplicationFiled: May 10, 2011Publication date: May 31, 2012Applicant: PERSEID THERAPEUTICS LLCInventors: MADAN M. PAIDHUNGAT, AMULYA NANISETTI, THOMAS BOUQUIN, KIM VILBOUR ANDERSEN, STEVEN J. CHAPIN, CLAUS KREBBER, RONG A. FAN, DANIEL MALASHOCK, AMY BRIDEAU-ANDERSEN, ERIK KARRER, BRUCE DEVENS, STEVEN H. BASS
-
Publication number: 20120129914Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: NOVARTIS AGInventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
-
Publication number: 20120129915Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: NOVARTIS AGInventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
-
Publication number: 20120129763Abstract: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate or carrying a Hofmann degradation of the primary amide of the 3rd amino acid asparagines with phenyl-bis-trifluoroacetate to give the primary amine.Type: ApplicationFiled: January 25, 2012Publication date: May 24, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Daniel Chu, Tao Ye
-
Publication number: 20120121709Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.Type: ApplicationFiled: September 26, 2011Publication date: May 17, 2012Inventors: Ashutosh Chilkoti, Felipe Garcia Quiroz, Miriam Amiram
-
Publication number: 20120122960Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: NOVARTIS AGInventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
-
Publication number: 20120121658Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.Type: ApplicationFiled: November 9, 2011Publication date: May 17, 2012Applicant: BIOTRONIK AGInventors: Alexander Borck, Matthias Gratz, Horst Kessler, Michael Joner, Florian Rechenmacher, Stefanie Neubauer
-
Publication number: 20120122800Abstract: This invention provides a unique composition which includes a DNA dendrimer combined with siRNA molecule. Further, methods of preparing a composition which includes a DNA dendrimer combined with a siRNA molecule, methods of protecting a DNA dendrimer siRNA complex against degradation in body fluids, methods of protecting a DNA dendrimer against degradation in bodily fluids, and methods of delivering a DNA dendrimer into bodily fluids are provided.Type: ApplicationFiled: August 10, 2009Publication date: May 17, 2012Inventors: James Kadushin, Robert C. Getts
-
Publication number: 20120121659Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.Type: ApplicationFiled: November 9, 2011Publication date: May 17, 2012Applicant: BIOTRONIK AGInventors: Alexander Borck, Matthias Gratz, Horst Kessler, Michael Joner, Florian Rechenmacher, Stefanie Neubauer
-
Publication number: 20120121537Abstract: Compositions and methods for reducing hepatitis C virus (HCV) replication are provided. Also provided are compositions and methods of treating an HCV infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection.Type: ApplicationFiled: January 11, 2010Publication date: May 17, 2012Inventors: Chaomin Sun, James Harrison Doudna Cate
-
Publication number: 20120122801Abstract: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Applicant: Prosensa B.V.Inventor: Gerard Johannes PLATENBURG
-
Publication number: 20120116027Abstract: The present invention relates to a novel process for the purification of growth hormone polypeptides, e.g. recombinant human Growth Hormone. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of Growth Hormone from closely related proteins.Type: ApplicationFiled: November 13, 2009Publication date: May 10, 2012Inventors: Jakob Ewald Rasmussen, Phaedria Marie St. Hilaire, Michael Roice, Christine Bruun Schioedt, Knud Jørgen Jensen
-
Publication number: 20120115933Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew SPRAGUE
-
Publication number: 20120114558Abstract: The present invention relates to aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Through these complexes, the present invention provides a means for establishing a drug reservoir in a subject, whereby drug may be released as needed. One specific embodiment of the invention provides an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine.Type: ApplicationFiled: September 26, 2011Publication date: May 10, 2012Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Milan N. Stojanovic, Renjun Pei, Steven Michael Forna Taylor
-
Publication number: 20120115136Abstract: The present invention pertains to certain nucleic acid analogs and related kits that are useful for the capture, recognition, detection, identification, or quantification of certain chemical or biological entities.Type: ApplicationFiled: July 25, 2011Publication date: May 10, 2012Applicant: PNA Patent Owners (a/k/a CIG)Inventors: Ole Buchardt, Michael Egholm, Peter E. Nielsen, Rolf H. Berg
-
Publication number: 20120107798Abstract: The various embodiments of the present disclosure relate generally to single molecule sensitive probes for detecting RNA, and more particularly to multivalent fluorescent probes for detecting a single molecule of RNA in a cell. The present invention includes a RNA imaging probe comprising: a multivalent core comprising a plurality of attachment sites; a plurality of RNA/DNA chimeric oligonucleotides having a specificity for a target RNA, wherein a RNA/DNA chimeric oligonucleotide is bound to an attachment site of the multivalent core; and a plurality of fluorophores, wherein a fluorophore is bound to the RNA/DNA chimeric oligonucleotide.Type: ApplicationFiled: March 25, 2010Publication date: May 3, 2012Applicant: GEORGIA TECH RESEARCH CORPORATIONInventor: Philip J. Santangelo
-
STRUCTURAL AND MECHANISTIC BASIS FOR NOVEL COMPOUND BIOSYNTHESIS USING THE 4-ELECTRON HEXOSE OXIDASE
Publication number: 20120108498Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: ApplicationFiled: October 1, 2010Publication date: May 3, 2012Applicant: Academia SinicaInventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu -
Publication number: 20120107243Abstract: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.Type: ApplicationFiled: July 14, 2010Publication date: May 3, 2012Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Geoffry L. Curran, Gobinda Sarkar, Joseph F. Poduslo, Robert B. Jenkins, Val J. Lowe, Eric W. Mahlum
-
Publication number: 20120107902Abstract: The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed.Type: ApplicationFiled: October 25, 2011Publication date: May 3, 2012Applicant: EMORY UNIVERSITYInventors: Lanny S. Liebeskind, Wenting Wu, Zhihui Zhang, Hao Li, Angus A. Lamar
-
Publication number: 20120107335Abstract: The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis, which can be used in the immunomodulation of individuals having immunocompetent systems and in the production of IgY polyclonal antibodies. The invention relates to a first method for obtaining a composition of IgY polyclonal antibodies that can be used as a diagnostic reagent having low cost and high reactivity in respect of intradomiciliary mites, and a second method for the detection of mite allergens, using the IgY antibody composition developed in the first method. The invention further relates to the composition of the IgY polyclonal antibodies.Type: ApplicationFiled: March 17, 2010Publication date: May 3, 2012Applicants: PONTIFICIA UNIVERSIDAD JAVERIANA, FUNDACION UNIVERSIDAD DEL NORTEInventors: Luis Alejandro Barrera, Eduardo Egea, Johana Espejo, Catalina Sosa, Elkin Navarro, Gloria Garavito, Dary Luz Mendoza
-
Publication number: 20120108504Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.Type: ApplicationFiled: June 25, 2010Publication date: May 3, 2012Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: Laszlo Otvos, JR.
-
Publication number: 20120101045Abstract: The disclosure provides fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders.Type: ApplicationFiled: May 7, 2010Publication date: April 26, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Steven F. Dowdy, Akiko Eguchi
-
Publication number: 20120101043Abstract: Methods and materials are provided for the production of glycosylated peptides that exhibit high affinity and specificity for delta opioid receptors. The methods and materials of the present invention may be used for treatment of conditions involving pain, such as acute pain and nociceptic pain, neuralgia and myalgia.Type: ApplicationFiled: December 8, 2009Publication date: April 26, 2012Applicant: BIOUSIAN BIOSYSTEM, INC.Inventors: Robin Polt, Edward J. Bilsky
-
Publication number: 20120101254Abstract: Reagents and methods for functionalising polypeptides with moieties poly (alkylene glycol) molecules and glycan groups are disclosed that are based on a functionalising reagent which comprises a nitrogen containing heterocyclic aromatic ring having a vinyl substituent that is capable of reacting with one or more thiol groups that are naturally present, or have been introduced into, the polypeptide, for example by employing a thiol group of one or more cysteine residues. The functionalising reagent is covalently linked to a poly (alkylene glycol) molecule, such as a polyethylene glycol (PEG) molecule, or a glycan group so that the reaction between the vinyl group and the thiol group in the polypeptide covalently links the polypeptide to the poly (alkylene glycol) molecule and/or the glycan group.Type: ApplicationFiled: December 21, 2009Publication date: April 26, 2012Inventors: Andrew Graham Watts, Terrence Kantner, Amanda Barbara MacKenze
-
Publication number: 20120100172Abstract: The present invention relates to immunogenic peptides, including variants and analogs derived from Streptococcus pneumoniae (S. pneumoniae) proteins, to peptide-multimers, conjugates and fusion proteins that include such peptides, and to vaccines that include such immunogenic entities. In particular, the present invention relates to the use of such vaccines for eliciting protective immunity to S. pneumoniae.Type: ApplicationFiled: June 3, 2010Publication date: April 26, 2012Inventors: Michael Tal, Maxim Portnoi, Ron Dagan, Yaffa Mizrachi-Nebenzahl
-
Publication number: 20120100633Abstract: The present invention relates to new methods and reagents for coupling molecules by a Click reaction using a heterogeneous catalyst system.Type: ApplicationFiled: April 8, 2010Publication date: April 26, 2012Applicant: BASECLICK GMBHInventors: Antonio Manetto, Philipp Mathias Edwin Gramlich, Simon Warncke
-
Patent number: 8163872Abstract: A novel and improved method for purification of glycopeptides, especially glycopeptide antibiotics. The method comprises contacting a solution of the glycopeptide to an ion exchange chromatography material. The product of this method has a surprisingly high purity.Type: GrantFiled: October 27, 2005Date of Patent: April 24, 2012Assignee: Xellia Pharmaceuticals APSInventors: Lene Aassveen, Kamilla Lundhaug, Kjersti Aastorp Hirth
-
Publication number: 20120094933Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: ApplicationFiled: August 18, 2009Publication date: April 19, 2012Inventors: Christopher Michejda, Maria Michejda, Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek
-
Publication number: 20120093846Abstract: Fusion protein for immunocastration (Sequences 1a and 1b) that comprises the primary amino acid sequence of the gonadotrophin-liberating protein fused to a theoretical sequence: NH2-QHWSYGLRPGGPPFSGGGGPPFSA-COOH??Sequence 1a NH2-GPPFSGGGGPPFSAQHWSYGLRPG-COOH;??Sequence 1b DNA sequences coding for said fusion protein; vaccine comprising said fusion protein; use of the fusion protein for mammal immunocastration; process for producing the vaccine; process for preparing the fusion protein that comprises fusing the amino acid sequence of the gonadotrophin-liberating hormone (GnRH-I) to a theoretical glycosilable sequence having immunogenic activity that does not include pathogen or “carrier” protein sequences in its structure.Type: ApplicationFiled: April 14, 2010Publication date: April 19, 2012Inventor: Leonardo Enrique Saenziturriaga
-
Publication number: 20120094934Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.Type: ApplicationFiled: June 24, 2010Publication date: April 19, 2012Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sheman
-
Publication number: 20120094892Abstract: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.Type: ApplicationFiled: March 9, 2010Publication date: April 19, 2012Applicant: KTB TUMORFORSCHUNGSGESELLSCHAFT MBHInventors: Felix Kratz, Andre Warnecke, Bakheet Elsadek
-
Publication number: 20120094924Abstract: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.Type: ApplicationFiled: October 13, 2011Publication date: April 19, 2012Applicant: Nitto Denko CorporationInventors: Padmanabh Chivukula, Jian Liu, Akinobu Soma, Keisaku Okada, Sang Van, Chen-Chang Lee, Lei Yu
-
Publication number: 20120091005Abstract: Methods, systems, and compounds for detecting modified nucleic acid bases are disclosed and described. The methods provide for detecting a nucleic acid lesion and can include directing a nucleic acid adduct into a channel, wherein the nucleic acid adduct includes a nucleic acid having a lesion and a current modulating compound coupled to the nucleic acid at the lesion (110), and measuring a change in current through the channel in response to the current modulating compound to detect the lesion (112). The method can optionally include forming the nucleic acid adduct. Also provided is a method for identifying the number of repeat nucleotides in at least a portion of a nucleic acid strand, a method of assigning a registration marker within a nucleic acid, and a method of obtaining sequence information from a nucleic acid comprising assigning a registration marker on the nucleic acid.Type: ApplicationFiled: September 7, 2011Publication date: April 19, 2012Inventors: Cynthia J. Burrows, Henry S. White, Ryuji Kawano, Aaron M. Fleming, Na An
-
Patent number: 8158750Abstract: This invention provides compositions and methods for stimulating the immune system. Such methods include administering an extract, purified peptide-linked glucan or active component thereof from Coriolus versicolor. The methods are particularly useful for prophylactic and therapeutic treatment of secondary immunodeficiency, wherein the immunodeficiency is the result of an infection, a malignant neoplastic disease, an autoimmune disease, a protein losing state, an immunosuppressive treatment, surgery or anesthesia.Type: GrantFiled: November 22, 2005Date of Patent: April 17, 2012Assignee: The Chinese University of Hong KongInventors: Albert H. L. Chow, Kevin K. W. Chu
-
Publication number: 20120083440Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.Type: ApplicationFiled: October 5, 2011Publication date: April 5, 2012Inventors: William M. Pierce, JR., K. Grant Taylor, Leonard C. Waite, Kevyn Merten
-
Publication number: 20120070897Abstract: Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.Type: ApplicationFiled: February 23, 2010Publication date: March 22, 2012Inventors: Toshihisa Hatta, Eriko Shimamura, Hiroki Shimada
-
Publication number: 20120071443Abstract: Materials and methods for studying and modulating the interaction of carbohydrate-containing moieties with other species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilising a plurality of ligands comprising carbohydrate groups. These “nanoparticles” can then be used to study carbohydrate mediated interactions, e.g. with other carbohydrates or proteins, and as therapeutics and diagnostic reagents.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Applicant: Midatech LimitedInventors: Soledad Penades, Javier Rojo, Manuel Martin-Lomas
-
Publication number: 20120070875Abstract: The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases.Type: ApplicationFiled: May 27, 2010Publication date: March 22, 2012Inventor: Richard H. Weisbart
-
Patent number: 8138304Abstract: Neural regeneration peptide consisting of a sequence comprised in the sequence of REGRRAAPGRAGG(SEQ ID NO:1).Type: GrantFiled: May 5, 2006Date of Patent: March 20, 2012Assignee: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Margaret Anne Brimble, Victoria Justine Muir
-
Publication number: 20120064109Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: ApplicationFiled: October 7, 2011Publication date: March 15, 2012Applicant: THE UNIVERSITY OF MELBOURNEInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
-
Publication number: 20120065149Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.Type: ApplicationFiled: September 7, 2011Publication date: March 15, 2012Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
-
Publication number: 20120065134Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: ApplicationFiled: July 13, 2009Publication date: March 15, 2012Inventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20120064048Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.Type: ApplicationFiled: May 18, 2010Publication date: March 15, 2012Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman
-
Publication number: 20120063276Abstract: A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid.Type: ApplicationFiled: November 7, 2011Publication date: March 15, 2012Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Meital Reches, Ehud Gazit
-
Publication number: 20120064110Abstract: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus hemagglutinin.Type: ApplicationFiled: August 19, 2011Publication date: March 15, 2012Applicant: Selecta Biosciences, Inc.Inventors: Petr Ilyinskii, Yun Gao, Fen-ni Fu, Grayson B. Lipford
-
Publication number: 20120064108Abstract: Glycoconjugate vaccines and methods of preparing and using the same are described.Type: ApplicationFiled: January 8, 2010Publication date: March 15, 2012Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Fikri Avci, Dennis L. Kasper